Plain-English translation of NCT07488819 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at Yale University are using a special type of brain imaging called PET scanning with a radioactive tracer called [18F] to study a protein in the brain called PDE4B. This protein may play a role in PTSD and alcohol use disorder. By comparing brain images from people with these conditions to people without them, scientists hope to better understand what happens in the brain and develop better treatments.
Current treatments for PTSD and alcohol use disorder don't work well for everyone. By studying how this brain protein differs in people with these conditions, researchers hope to find new ways to help patients and eventually create more effective treatments.
You likely qualify if…
You likely don't qualify if…
Participants will come to Yale University for brain imaging appointments where they receive an injection of the radioactive tracer and then undergo a PET scan — a type of imaging that shows how the brain is working. The study compares people with PTSD, people with alcohol use disorder, healthy people with no psychiatric history, and people who have experienced trauma but did not develop PTSD. All participants will undergo the same imaging procedures and answer questions about their medical and mental health history.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Sponsor
Yale University
Enrollment target
~160 participants
Started
July 2025
Primary completion
March 2031
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marc V Grasso
Yale University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.